Molecular Targets Phase III CoBRE

分子靶标 III 期 CoBRE

• 批准号: 8687689
• 负责人: Donald M. Miller
• 金额: $ 109.72万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-01 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8687689
• 关键词: Accounting; Animal Model; Antineoplastic Agents; Area; Biostatistics Core; Cancer Center; Cell Separation; Centers of Research Excellence; Clinical Trials; Core Facility; Development; Ensure; Faculty; Flow Cytometry; Funding; Goals; Growth; Human; Institution; Leadership; Malignant Neoplasms; Molecular Models; Molecular Target; Phase; Research; Research Infrastructure; Research Personnel; Role; Testing; Training; Translating; Translational Research; United States National Institutes of Health; Universities; cancer therapy; career; drug development; drug discovery; inhibitor/antagonist; member; metabolomics; molecular modeling; novel; novel therapeutics; pre-clinical; programs; public health relevance; success; tumor metabolism

DESCRIPTION (provided by applicant): The Molecular Targets Center of Biomedical Research Excellence (MT COBRE) at the University of Louisville and the James Graham Brown Cancer Center has successful supported the early career of fourteen junior faculty members during its Phase I and il funding periods. The current application reflects the maturation of the Molecular Targets Program and its faculty. The overall goal of the Phase III application of the Molecular Targets COBRE will be to ensure that the novel targets and compounds which have been identified by MT COBRE faculty are translated to pivotal human clinical trials. Several strengths have enhanced the success of this program including: 1) Stability of program leadership; 2) Successful retention of all fourteen faculty members; 3) Institutional support for the program totaling over $30M; and 4) Creation of a University of Louisville-owned company dedicated to translating important discoveries of MT COBRE investigators. The ability of MT COBRE faculty to test their novel compounds in humans will distinguish this program from similar programs at other institutions.' To this end, the MT COBRE has supported the development of a unique translational research infrastructure which has enabled the characterization of more than 30 novel targets. The Phase III application will support four closely integrated core facilities which will support this goal; 1) Microarray Core; 2) Molecular Modeling Core; 3) NMR/Metabolomic Core and 4) Animal Model Core. Additionally, the James Graham Brown Cancer Center has created complementary research cores which will be available to MT Program members during the Phase III component of the program including the Biostatistics Core, Clinical Trials Office, Biophysical Cancer Core, Cell Sorting and Flow Cytometry Core. The MT COBRE administration will continue to provide intensive support for development of the fourteen faculty members, many of whom have assumed leadership roles within the Cancer Center and University. The robust translational research infrastructure at the James Graham Brown Cancer Center and University of Louisville will ensure the success and sustainability of this unique program.

描述（由申请人提供）：路易斯维尔大学生物医学研究卓越分子目标中心 (MT COBRE) 和詹姆斯格雷厄姆布朗癌症中心在第一阶段和第二阶段资助期间成功支持了 14 名初级教员的早期职业生涯。目前的申请反映了分子目标计划及其师资力量的成熟。分子靶点 COBRE 的 III 期应用的总体目标是确保 MT COBRE 教师确定的新靶点和化合物转化为关键的人体临床试验。多项优势促进了该计划的成功，包括： 1) 计划领导层的稳定性； 2) 成功保留所有十四名教职人员； 3) 对该计划的机构支持总额超过 3000 万美元； 4) 创建路易斯维尔大学旗下的公司，致力于翻译 MT COBRE 研究人员的重要发现。 MT COBRE 教师在人体中测试其新型化合物的能力将使该项目与其他机构的类似项目区分开来。为此，MT COBRE 支持开发独特的转化研究基础设施，该基础设施已能够表征 30 多个新靶标。第三阶段的应用将密切支持四个 支持这一目标的综合核心设施； 1) 微阵列核心； 2）分子建模核心； 3) NMR/代谢组学核心和 4) 动物模型核心。此外，James Graham Brown 癌症中心还创建了补充研究核心，将在该计划的第三阶段部分向 MT 计划成员提供，包括生物统计核心、临床试验办公室、生物物理癌症核心、细胞分选和流式细胞术核心。 MT COBRE 管理层将继续为 14 名教职人员的发展提供大力支持，其中许多人在癌症中心和大学中担任领导职务。詹姆斯·格雷厄姆·布朗癌症中心和路易斯维尔大学强大的转化研究基础设施将确保这一独特项目的成功和可持续性。